Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Paradigm Biopharmaceuticals ( (AU:PAR) ) has provided an update.
Paradigm Biopharmaceuticals has applied to the ASX for quotation of 176,880 new ordinary fully paid shares following the exercise or conversion of existing options or other convertible securities, with an issue date of 3 February 2026. The modest increase in quoted securities slightly expands the company’s capital base and free float, reflecting ongoing utilisation of equity-linked instruments but not indicating any major change to its operational strategy or market positioning at this time.
The most recent analyst rating on (AU:PAR) stock is a Hold with a A$0.31 price target. To see the full list of analyst forecasts on Paradigm Biopharmaceuticals stock, see the AU:PAR Stock Forecast page.
More about Paradigm Biopharmaceuticals
Paradigm Biopharmaceuticals Limited is an Australian-listed biopharmaceutical company (ASX: PAR) focused on developing and commercialising pharmaceutical therapies, operating within the broader life sciences and healthcare sector.
Average Trading Volume: 902,057
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$132.2M
For detailed information about PAR stock, go to TipRanks’ Stock Analysis page.